|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the frequency of p15(INK4B) methylation was significantly higher in patients with MM than in those with asymptomatic monoclonal gammopathy of undetermined significance.
|
25382971 |
2014 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current meta-analysis confirms and reinforces existing findings that p15 (INK4b) and p16 (INK4a) promoter methylation may be closely implicated in the pathogenesis of MM.
|
24908414 |
2014 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest methylation of TP73, ARF, p15 INK4B , and p16 INK4A as early events in the pathogenesis and development of plasma cell disorders; meanwhile, SOCS-1 methylation would be an important step in the clonal evolution from MGUS to MM.
|
19727727 |
2010 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The QMSP analyses showed that PTGS2 (100.0%), SFN (100.0%), CDKN2B (90.2%), CDH1 (88.2%), ESR1 (72.5%), HIC1 (70.5%), CCND2 (62.7%), DCC (45.1%) and TGFbetaR2 (39.2%) are frequently hypermethylated in MM while aberrant methylation of RARbeta (16.6%), MGMT (12.5%), AIM1 (12.5%), CDKN2A (8.3%), SOCS1 (8.3%), CCNA1 (8.3%) and THBS1 (4.1%) are rare events.
|
19548309 |
2009 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
p14/p16 and p15 gene expression was assessed by quantitative polymerase chain reaction in purified plasma cells (PC) from 52 patients with symptomatic multiple myeloma (MM) and seven with smoldering MM in order to clarify the impact of these genes on the proliferative activity of tumor cells and patients' outcome. p15 expression was lower in symptomatic MM than in smoldering SMM (-1.80 vs.1.51,p=0.026); similar results were observed for p14/p16.
|
17043023 |
2006 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The methylation patterns of the genes p16(INK4a) (p16), tissue inhibitor of metalloproteinase 3 (TIMP3), p15(INK4b) (p15), E-cadherin (ECAD), death-associated protein kinase (DAPK), p73, RAS-association domain family 1A (RASSF1A), p14, O(6)-methylguanine DNA methyltransferase (MGMT), and retinoid acid receptor beta2 (RARbeta) were determined in patients with monoclonal gammopathy of undetermined significance (MGUS; n = 29), smoldering multiple myeloma (SMM; n = 5), multiple myeloma (MM; n = 113), or plasma cell leukemia (PCL; n = 7) by methylation-specific polymerase chain reaction analysis.
|
15197802 |
2004 |
|
Multiple Myeloma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In analyses using DNAs extracted from bone marrow mononuclear cells (BM-MNCs), patients with multiple myeloma (MM) showed frequent hypermethylation of the p16INK4A gene (15/37, 41%), whereas p15INK4B gene methylation was not so frequent (5/37, 14%).
|
11243384 |
2001 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Selective methylation was found in 19% for p16(INK4a), 36% for p15(INK4b), and 6.5% for both genes in MGUS, and frequencies were similar in MM suggesting that methylation of these genes is an early event, not associated with transition from MGUS to MM. p15(INK4b) and p16(INK4a) gene methylation might contribute to immortalization of plasma cells rather than malignant transformation in the natural history of MM.
|
11418489 |
2001 |
|
Multiple Myeloma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our results in studies with cell lines and primary MM support the fact that hypermethylation of p16 and p15 plays an important role in MM tumorigenesis.
|
10492069 |
1999 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, p15 is most often inactivated, at particularly high frequencies in the disorders lacking any p15/p16 deletions: 40-80% p15met in AML, MDS and multiple myeloma.
|
9639410 |
1998 |
|
Multiple Myeloma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The present data show that the p16 and p15 genes are silenced in MM by hypermethylation, which may play an important role in MM pathogenesis.
|
9792305 |
1998 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One myeloma case had a p15 gene homozygous deletion (6%) with an intact p16 gene.
|
9012694 |
1997 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, hypermethylation was observed in 75% for p16 and 67% for p15 in our group of MM patients.
|
9116295 |
1997 |